Events

Trending on OncLive

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs

EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma

Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026

BCG-Unresponsive NMIBC Treatment Selection Requires Balancing Durability, Toxicity, and Patient Priorities